Discovery, development and optimisation of a novel frog antimicrobial peptide with combined mode of action against drug-resistant bacteria

Bibliographic Details
Title: Discovery, development and optimisation of a novel frog antimicrobial peptide with combined mode of action against drug-resistant bacteria
Authors: Jingkai Wang, Jibo Hu, Wenyuan Pu, Xiaoling Chen, Chengbang Ma, Yangyang Jiang, Tao Wang, Tianbao Chen, Chris Shaw, Mei Zhou, Lei Wang
Source: Computational and Structural Biotechnology Journal, Vol 23, Iss , Pp 3391-3406 (2024)
Publisher Information: Elsevier, 2024.
Publication Year: 2024
Collection: LCC:Biotechnology
Subject Terms: Antimicrobial peptide, Brevinin-1, Drug-resistant, LPS binding, DNA binding, Biotechnology, TP248.13-248.65
More Details: Antimicrobial peptides (AMP) have emerged as promising candidates for addressing the clinical challenges posed by the rapid evolution of antibiotic-resistant microorganisms. Brevinins, a representative frog-derived AMP family, exhibited broad-spectrum antimicrobial activities, attacking great attentions in previous studies. However, their strong haemolytic activity and cytotoxicity, greatly limit their further development. In this work, we identified and characterised a novel brevinin-1 peptide, brevinin-1pl, from the skin secretions of the northern leopard frog, Rana pipiens. Like many brevinins, brevinin-1pl also displayed strong haemolytic activity, resulting in a lower therapeutic index. We employed several bioinformatics tools to analyse the structure and potential membrane interactions of brevinin-1pl, leading to a series of modifications. Among these analogues, des-Ala16-[Lys4]brevinin-1pl exhibited great enhanced therapeutic efficacy in both in vitro and in vivo tests, particularly against some antibiotics-resistant Escherichia coli strains. Mechanistic studies suggest that des-Ala16-[Lys4]brevinin-1pl may exert bactericidal effects through multiple mechanisms, including membrane disruption and DNA binding. Consequently, des-Ala16-[Lys4]brevinin-1pl holds promise as a candidate for the treatment of drug-resistant Escherichia coli infections.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2001-0370
Relation: http://www.sciencedirect.com/science/article/pii/S2001037024002952; https://doaj.org/toc/2001-0370
DOI: 10.1016/j.csbj.2024.09.006
Access URL: https://doaj.org/article/83146f4b528c4da89ecf79dd836a0700
Accession Number: edsdoj.83146f4b528c4da89ecf79dd836a0700
Database: Directory of Open Access Journals
More Details
ISSN:20010370
DOI:10.1016/j.csbj.2024.09.006
Published in:Computational and Structural Biotechnology Journal
Language:English